XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

NCT03511170 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms
Chemotherapy

Interventions

DRUG: XELIRI
DRUG: XELOX

Sponsor

Harbin Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]